Literature DB >> 7779648

The effect of ranitidine on symptom relief and quality of life of patients with gastro-oesophageal reflux disease.

K L Chal1, J H Stacey, G E Sacks.   

Abstract

A 4-week study involving 354 patients with the symptoms of gastro-oesophageal reflux disease was conducted to assess the effect of ranitidine (as effervescent tablets) on their relief and quality of life. All patients received 150 mg bd for 2 weeks, with those responding to treatment continuing on the same dosage for a further 2-week period and 'non-responders' having the dosage increased to 150 mg qds for a further 2 weeks. Quality of life and symptom assessments were carried out at 0, 2 and 4 weeks. Two weeks' treatment with ranitidine 150 mg bd was effective at controlling the GORD symptoms in 78% of patients. A 4-week treatment with either 150 mg bd or qds controlled the symptoms in 85% of patients. All patients had significant improvements in all dimensions of their quality of life over the study period.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7779648

Source DB:  PubMed          Journal:  Br J Clin Pract        ISSN: 0007-0947


  10 in total

1.  Health-related quality of life of patients with acute erosive reflux esophagitis.

Authors:  S D Mathias; D O Castell; E P Elkin; M L Matosian
Journal:  Dig Dis Sci       Date:  1996-11       Impact factor: 3.199

2.  Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease.

Authors:  D A Revicki; M Wood; I Wiklund; J Crawley
Journal:  Qual Life Res       Date:  1998-01       Impact factor: 4.147

3.  Poorly treated or unrecognized GERD reduces quality of life in patients with COPD.

Authors:  Ivan E Rascon-Aguilar; Mark Pamer; Peter Wludyka; James Cury; Kenneth J Vega
Journal:  Dig Dis Sci       Date:  2011-01-08       Impact factor: 3.199

Review 4.  Patient reported outcomes in gastroesophageal reflux disease: an overview of available measures.

Authors:  Nicholas J Talley; Ingela Wiklund
Journal:  Qual Life Res       Date:  2005-02       Impact factor: 4.147

5.  Three clinical variants of gastroesophageal reflux disease form two distinct gene expression signatures.

Authors:  Jerzy Ostrowski; Tymon Rubel; Lucjan S Wyrwicz; Michal Mikula; Andrzej Bielasik; Eugeniusz Butruk; Jaroslaw Regula
Journal:  J Mol Med (Berl)       Date:  2006-08-04       Impact factor: 4.599

6.  Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease.

Authors:  John F Johanson; Reshmi Siddique; Anne M Damiano; Leonard Jokubaitis; Anita Murthy; Ashoke Bhattacharjya
Journal:  Dig Dis Sci       Date:  2002-11       Impact factor: 3.199

7.  Measuring symptom distress and health-related quality of life in clinical trials of gastroesophageal reflux disease treatment: further validation of the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS).

Authors:  Anne Damiano; Kathleen Handley; Ellen Adler; Reshmi Siddique; Ashoke Bhattacharyja
Journal:  Dig Dis Sci       Date:  2002-07       Impact factor: 3.199

Review 8.  The impact of treatment for gastro-oesophageal reflux disease on health-related quality of life: a literature review.

Authors:  Manishi Prasad; Anne M Rentz; Dennis A Revicki
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 9.  Improving health-related quality of life in gastro-oesophageal reflux disease.

Authors:  Michael J Shaw; Joseph A Crawley
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Health-related quality of life improves with treatment-related GERD symptom resolution after adjusting for baseline severity.

Authors:  Dennis A Revicki; Marc W Zodet; Sandra Joshua-Gotlib; Douglas Levine; Joseph A Crawley
Journal:  Health Qual Life Outcomes       Date:  2003-11-29       Impact factor: 3.186

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.